J. Van Lint
RecallSurvival analysisRisk assessmentInternal medicineAssociation (psychology)OncologyAdverse effectRheumatologyMedDRAVedolizumabCombination therapyInfliximabEtanerceptRheumatoid arthritisDiscontinuationTofacitinibDepression (differential diagnoses)HydroxychloroquineDiseaseImmune-mediated inflammatory diseasesAdalimumabAdverse drug reactionMethotrexatePopulationGastro intestinalDrug reactionIn patientLow dose methotrexateDrug survivalDisease specificPackage insertFamily medicineClinical trialDiabetes mellitusPharmacovigilanceMedicineCohort
7Publications
1H-index
0Citations
Publications 7
Newest
#1J. Van LintH-Index: 1
#2T. BakkerH-Index: 1
Last. Naomi T. JessurunH-Index: 6
view all 5 authors...
Source
Source
Background: null Information on adverse drug reactions (ADRs) is generally clustered for all indications of a drug in the patient information leaflet. However, previous research has shown that participants of the Dutch Biologic Monitor (DBM) that use a biologic for their immune-mediated inflammatory disease (IMID) prefer to receive ADR information tailored to their own biologic an IMID (1). Currently, it is unclear whether the ADR profile of a specific biologic may differ between patients with d...
Source
Source
#1J. Van LintH-Index: 1
#2Naomi T. JessurunH-Index: 6
Last. Harald E. Vonkeman (Medisch Spectrum Twente)H-Index: 26
view all 11 authors...
Background: Although an increased risk of inflammatory bowel disease (IBD) during etanercept (ETN) use is included in the product information of ETN, no other gastro-intestinal (GI-)adverse drug reactions (ADRs) are described. This is in contrast with other TNFα-inhibitors such as adalimumab (ADA) and infliximab, as these are associated with various GI-ADRs such as nausea and abdominal pain. Objectives: To identify the proportion and type of patient-reported and health care professional (HCP)-re...
Source
#1A. Laurijssen (Radboud University Nijmegen)
#2J. Van LintH-Index: 1
Last. Naomi T. JessurunH-Index: 6
view all 5 authors...
Background: In order to monitor the safety of medicines pharmacovigilance, it is important that patients report their adverse drug reactions (ADRs). Theoretically, the quality of the reported information might be affected by the elapsed time between the onset of the ADR and the moment of reporting. Real-life evidence demonstrating a negative relationship between this recall period and the quality of reported ADRs is however lacking. Objectives: To assess the effect of recall period on the amount...
Source
Background: Chronic fatigue is a well-known symptom in patients with rheumatic diseases and other immune-mediated inflammatory diseases (IMIDs). Therefore, fatigue as an adverse drug reaction (ADR) to biologics may remain unrecognised or may erroneously be attributed to the disease. Objectives: To assess patient-reported fatigue attributed to biologics for IMIDs and investigate predisposing factors of patient-reported fatigue. Methods: The Dutch Biologic Monitor is a multicenter patient-reported...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.